RadNet, has obtained FDA clearance for the third-generation launch of its Quantib Prostate 3.0 MRI synthetic intelligence (AI) software program, enhancing the providing with up to date instruments.
Quantib Prostate software program for MRI studying assist was first launched within the US, adopted by a category IIb CE marking in Europe in 2021.
Quantib Prostate 3.0 is an AI-based software program resolution that advances the MRI prostate reporting workflow and its output for radiologists and urologists. It supplies a set of instruments to enhance reporting high quality and velocity, together with AI-based segmentations and volumetry, PSA density calculation, exact registration and motion correction, one-click segmentation of lesion candidates, PI-RADS scoring assist, and standardised reporting to facilitate straightforward and complete communication of outcomes.
The FDA 510(okay) particular clearance introduces an improve to the newest Quantib Prostate 2.1 launch. The upcoming launch of the product will embody an improved prostate and sub-region segmentation algorithm, automated drawing of the lesions on the PI-RADS sector map, and different functionalities that can improve the consumer expertise.
Arthur Publish Uiterweer, CEO of Quantib, mentioned: “We’re excited to current this replace of Quantib Prostate, which permits us to proceed to assist our clients with the latest developments and improved AI algorithm efficiency. We try to usually and constantly enhance our software program so as to assist radiologists and urologists in the absolute best approach.”
Gregory Sorensen, M.D., president of RadNet’s AI Division, added: “The approval of Quantib Prostate 3.0 represents one other step ahead in advancing prostate most cancers care by bringing the newest in AI expertise to MRI interpretation. With the growing recognition of the essential function MRI performs in prostate most cancers prognosis, physicians worth the ability that this software program places of their palms much more.”
RadNet, has obtained FDA clearance for the third-generation launch of its Quantib Prostate 3.0 MRI synthetic intelligence (AI) software program, enhancing the providing with up to date instruments.
Quantib Prostate software program for MRI studying assist was first launched within the US, adopted by a category IIb CE marking in Europe in 2021.
Quantib Prostate 3.0 is an AI-based software program resolution that advances the MRI prostate reporting workflow and its output for radiologists and urologists. It supplies a set of instruments to enhance reporting high quality and velocity, together with AI-based segmentations and volumetry, PSA density calculation, exact registration and motion correction, one-click segmentation of lesion candidates, PI-RADS scoring assist, and standardised reporting to facilitate straightforward and complete communication of outcomes.
The FDA 510(okay) particular clearance introduces an improve to the newest Quantib Prostate 2.1 launch. The upcoming launch of the product will embody an improved prostate and sub-region segmentation algorithm, automated drawing of the lesions on the PI-RADS sector map, and different functionalities that can improve the consumer expertise.
Arthur Publish Uiterweer, CEO of Quantib, mentioned: “We’re excited to current this replace of Quantib Prostate, which permits us to proceed to assist our clients with the latest developments and improved AI algorithm efficiency. We try to usually and constantly enhance our software program so as to assist radiologists and urologists in the absolute best approach.”
Gregory Sorensen, M.D., president of RadNet’s AI Division, added: “The approval of Quantib Prostate 3.0 represents one other step ahead in advancing prostate most cancers care by bringing the newest in AI expertise to MRI interpretation. With the growing recognition of the essential function MRI performs in prostate most cancers prognosis, physicians worth the ability that this software program places of their palms much more.”
RadNet, has obtained FDA clearance for the third-generation launch of its Quantib Prostate 3.0 MRI synthetic intelligence (AI) software program, enhancing the providing with up to date instruments.
Quantib Prostate software program for MRI studying assist was first launched within the US, adopted by a category IIb CE marking in Europe in 2021.
Quantib Prostate 3.0 is an AI-based software program resolution that advances the MRI prostate reporting workflow and its output for radiologists and urologists. It supplies a set of instruments to enhance reporting high quality and velocity, together with AI-based segmentations and volumetry, PSA density calculation, exact registration and motion correction, one-click segmentation of lesion candidates, PI-RADS scoring assist, and standardised reporting to facilitate straightforward and complete communication of outcomes.
The FDA 510(okay) particular clearance introduces an improve to the newest Quantib Prostate 2.1 launch. The upcoming launch of the product will embody an improved prostate and sub-region segmentation algorithm, automated drawing of the lesions on the PI-RADS sector map, and different functionalities that can improve the consumer expertise.
Arthur Publish Uiterweer, CEO of Quantib, mentioned: “We’re excited to current this replace of Quantib Prostate, which permits us to proceed to assist our clients with the latest developments and improved AI algorithm efficiency. We try to usually and constantly enhance our software program so as to assist radiologists and urologists in the absolute best approach.”
Gregory Sorensen, M.D., president of RadNet’s AI Division, added: “The approval of Quantib Prostate 3.0 represents one other step ahead in advancing prostate most cancers care by bringing the newest in AI expertise to MRI interpretation. With the growing recognition of the essential function MRI performs in prostate most cancers prognosis, physicians worth the ability that this software program places of their palms much more.”
RadNet, has obtained FDA clearance for the third-generation launch of its Quantib Prostate 3.0 MRI synthetic intelligence (AI) software program, enhancing the providing with up to date instruments.
Quantib Prostate software program for MRI studying assist was first launched within the US, adopted by a category IIb CE marking in Europe in 2021.
Quantib Prostate 3.0 is an AI-based software program resolution that advances the MRI prostate reporting workflow and its output for radiologists and urologists. It supplies a set of instruments to enhance reporting high quality and velocity, together with AI-based segmentations and volumetry, PSA density calculation, exact registration and motion correction, one-click segmentation of lesion candidates, PI-RADS scoring assist, and standardised reporting to facilitate straightforward and complete communication of outcomes.
The FDA 510(okay) particular clearance introduces an improve to the newest Quantib Prostate 2.1 launch. The upcoming launch of the product will embody an improved prostate and sub-region segmentation algorithm, automated drawing of the lesions on the PI-RADS sector map, and different functionalities that can improve the consumer expertise.
Arthur Publish Uiterweer, CEO of Quantib, mentioned: “We’re excited to current this replace of Quantib Prostate, which permits us to proceed to assist our clients with the latest developments and improved AI algorithm efficiency. We try to usually and constantly enhance our software program so as to assist radiologists and urologists in the absolute best approach.”
Gregory Sorensen, M.D., president of RadNet’s AI Division, added: “The approval of Quantib Prostate 3.0 represents one other step ahead in advancing prostate most cancers care by bringing the newest in AI expertise to MRI interpretation. With the growing recognition of the essential function MRI performs in prostate most cancers prognosis, physicians worth the ability that this software program places of their palms much more.”
